Psoriasis: biologic therapy eases fatigue in meta-analysis

  • Skoie IM & al.
  • Am J Clin Dermatol
  • 2 Apr 2019

  • International Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Biologic therapy is associated with a reduction in fatigue among patients with psoriasis, according to a systematic review and meta-analysis.

Why this matters

  • Fatigue is a common problem in patients with psoriasis.

Key results

  • Biologic treatment was associated with a reduction in fatigue compared with placebo (standardized mean difference, −0.40; P<.001>
  • There was no evidence of effect differences between different biological agents.

Study design

  • 8 randomized controlled trials (n=6033 patients) were included in the meta-analysis.
  • Included studies used either the Short Form-36 Vitality Subscale or Functional Assessment of Chronic Illness Therapy-Fatigue to score fatigue.
  • Biologic agents studied included infliximab (Remicade), adalimumab (Humira), etanercept (Enbrel), ustekinumab (Stelara), and guselkumab (Tremfya).
  • Funding: Western Norway Regional Health Authority.

Limitations

  • Only PubMed was searched for relevant articles.
  • No long-term analysis of fatigue (included studies assessed fatigue at or before 16 weeks).

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit